IP Library › Patent Application 16997238

Patent Application

App. No. 16/997,238

TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 16/997,238

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Methods and polypeptides for conferring site-specific or local immune privilege.

Claims (104)

1 . A polypeptide comprising an anti-MAdCAM antibody and an anti-PD-1 antibody, wherein the polypeptide comprises a first polypeptide and a second polypeptide, wherein:

the first polypeptide comprises a variable heavy chain domain that binds to PD-1 with a variable light chain domain of the second polypeptide linked, directly or indirectly, to the anti-MAdCAM antibody; and

the second polypeptide comprises the variable light chain domain that binds to PD-1 with the variable heavy domain of the first polypeptide.

2 . The polypeptide of claim 1 , wherein:

the first polypeptide has a formula of:

V H -H c -Linker-C 1 , wherein:

VH is the variable heavy domain that binds to PD-1 with the variable light chain domain;

H c is a heavy chain of antibody comprising a CH1-CH2-CH3 domain,

the Linker is a peptide linker,

and C 1 is the anti-MAdCAM antibody; and

3 . The polypeptide of claim 1 , wherein the second polypeptide has the formula of:

V L -L c , wherein:

V L is the variable light chain domain; and

L c is a light chain domain.

4 . The polypeptide of claim 1 , wherein the peptide linker is a glycine/serine linker.

5 . (canceled)

6 . The polypeptide of claim 1 , wherein the anti-MAdCAM antibody is an scFV antibody, wherein the scFV antibody has a formula of:

VH SC -L SC -VL SC , wherein:

VH SC comprises a variable heavy chain domain that binds to MAdCAM in conjunction with the VL SC ;

L SC is a peptide linker; and

VL SC comprises a variable light chain domain that binds to MAdCAM in conjunction with the VH SC .

7 . (canceled)

8 . The polypeptide of claim 1 , wherein:

the first polypeptide has a formula of:

V H -H c -Linker-C 1 , wherein:

V H is the variable heavy domain that binds to PD-1 with the variable light chain domain;

H c is a heavy chain of antibody comprising a CH1-CH2-CH3 domain,

the Linker is a peptide linker,

and C 1 is the anti-MAdCAM antibody; and

the second polypeptide has the formula of:

V L -L c , wherein:

V L is the variable light chain domain; and

Lc is a light chain domain.

9 - 13 . (canceled)

14 . The polypeptide of claim 1 , wherein the anti-MAdCAM antibody comprises a sequence as illustrated in MAdCAM Antibody Table 1 or 2.

15 . The polypeptide of claim 1 , wherein the PD-1 antibody comprises a sequence as illustrated in PD-1 Antibody Table 4 or PD-1 Antibody Table 5.

16 - 17 . (canceled)

18 . The polypeptide of claim 1 , wherein the anti-MAdCAM antibody comprises a heavy chain variable region, wherein the heavy chain variable region is a heavy chain variable region of Clone ID: 6, 75, or 79 of MAdCAM Ab Table 2.

19 . The polypeptide of claim 1 , wherein the anti-MAdCAM antibody comprises a heavy chain variable region, wherein the heavy chain variable comprises the CDRs of the heavy domain of 6, 75, or 79 of MAdCAM Ab Table 2.

20 . (canceled)

21 . The polypeptide of claim 1 , wherein the anti-MAdCAM antibody comprises a heavy chain variable region, wherein the heavy chain variable region comprises:

a first CDR of SEQ ID NO: 359, a second CDR of SEQ ID NO: 170, and a third CDR of SEQ ID NO: 360;

a first CDR of SEQ ID NO: 90, a second CDR of SEQ ID NO: 91, and a third CDR of SEQ ID NO: 92; or

a first CDR of SEQ ID NO: 135, a second CDR of SEQ ID NO: 381, and a third CDR of SEQ ID NO: 382.

22 . (canceled)

23 . The polypeptide of claim 1 , wherein the anti-MAdCAM antibody comprises a light chain variable region that comprises a sequence of SEQ ID NO: 415, SEQ ID NO: 592 or SEQ ID NO: 600 or a VL sequence as provided for in MAdCAM Ab Table 2.

24 . The polypeptide of claim 22 , wherein the anti-MAdCAM antibody comprises a light chain variable region comprising:

a first CDR of SEQ ID NO: 361, a second CDR of SEQ ID NO: 362, and a third CDR of SEQ ID NO: 363;

a first CDR of SEQ ID NO: 93, a second CDR of SEQ ID NO: 87, and a third CDR of SEQ ID NO: 94; or

a first CDR of SEQ ID NO: 383, a second CDR of SEQ ID NO: 384, and a third CDR of SEQ ID NO: 385.

25 . (canceled)

26 . The polypeptide of claim 1 , wherein the anti-PD-1 antibody heavy chain variable region is a heavy chain variable region as provided for in PD-1 Antibody Table 4.

27 . The polypeptide of claim 1 , wherein the anti-PD-1 antibody heavy chain variable region is a heavy chain variable region of Clone ID: PD1AB4 (SEQ ID NO: 637), PD1AB30 (SEQ ID NO: 769), PD1AB17 (SEQ ID NO: 704), PD1AB18 (SEQ ID NO: 710), PD1AB20 (SEQ ID NO: 724), PD1AB25 (SEQ ID NO: 755) of PD-1 Antibody Table 4.

28 . (canceled)

29 . The polypeptide of claim 1 , wherein the anti-PD-1 antibody heavy chain variable region comprises a first CDR of SEQ ID NO: 639, 757, 706, 712, or 726, 757, a second CDR of SEQ ID NO: 69, 758, 707, 713, 727, or 758 and a third CDR of SEQ ID NO: 640, 759, 708, 714, 728, or 759.

30 . The polypeptide of claim 1 , wherein the anti-PD-1 antibody heavy chain variable region comprises:

a first CDR of SEQ ID NO: 639, a second CDR of SEQ ID NO: 69, and a third CDR of SEQ ID NO: 640;

a first CDR of SEQ ID NO: 757, a second CDR of SEQ ID NO: 758, and a third CDR of SEQ ID NO: 759;

a first CDR of SEQ ID NO: 706, a second CDR of SEQ ID NO: 707, and a third CDR of SEQ ID NO: 708;

a first CDR of SEQ ID NO: 712, a second CDR of SEQ ID NO: 713, and a third CDR of SEQ ID NO: 714; or

a first CDR of SEQ ID NO: 726, a second CDR of SEQ ID NO: 727, and a third CDR of SEQ ID NO: 728.

31 . The polypeptide of claim 1 , wherein the anti-PD-1 antibody light chain variable region is a light chain variable region of Clone ID: PD1AB4 (SEQ ID NO: 638), PD1AB30 (SEQ ID NO: 756), PD1AB17 (SEQ ID NO: 705), PD1AB18 (SEQ ID NO: 711), PD1AB20 (SEQ ID NO: 725), PD1AB25 (SEQ ID NO: 756) of PD-1 Antibody Table 4.

32 . (canceled)

33 . The polypeptide of claim 1 , wherein the anti-PD-1 antibody light chain variable region comprises a first CDR of SEQ ID NO: 641, 709, 715, 729, or 760 a second CDR of SEQ ID NO: 362, 716, 420, or 378, and a third CDR of SEQ ID NO: 642, 421, 717, 730, or 761.

34 . The polypeptide of claim 1 , wherein the anti-PD-1 antibody light chain variable region comprises:

a first CDR of SEQ ID NO: 641, a second CDR of SEQ ID NO: 362, and a third CDR of SEQ ID NO: 642;

a first CDR of SEQ ID NO: 709, a second CDR of SEQ ID NO: 362, and a third CDR of SEQ ID NO: 421;

a first CDR of SEQ ID NO: 715, a second CDR of SEQ ID NO: 716, and a third CDR of SEQ ID NO: 717;

a first CDR of SEQ ID NO: 729, a second CDR of SEQ ID NO: 420, and a third CDR of SEQ ID NO: 730; or

a first CDR of SEQ ID NO: 760, a second CDR of SEQ ID NO: 378, and a third CDR of SEQ ID NO: 761.

35 . The polypeptide of claim 1 , wherein the anti-PD-1 antibody comprises:

a heavy chain variable region comprising a first CDR of SEQ ID NO: 639, a second CDR of SEQ ID NO: 69, and a third CDR of SEQ ID NO: 640 and a light chain variable region comprising a first CDR of SEQ ID NO: 641, a second CDR of SEQ ID NO: 362, and a third CDR of SEQ ID NO: 642;

a heavy chain variable region comprising a first CDR of SEQ ID NO: 757, a second CDR of SEQ ID NO: 758, and a third CDR of SEQ ID NO: 759 and a light chain variable region comprising a first CDR of SEQ ID NO: 760, a second CDR of SEQ ID NO: 378, and a third CDR of SEQ ID NO: 761;

a heavy chain variable region comprising a first CDR of SEQ ID NO: 706, a second CDR of SEQ ID NO: 707, and a third CDR of SEQ ID NO: 708 and a light chain variable region comprising a first CDR of SEQ ID NO: 709, a second CDR of SEQ ID NO: 362, and a third CDR of SEQ ID NO: 421;

a heavy chain variable region comprising a first CDR of SEQ ID NO: 712, a second CDR of SEQ ID NO: 713, and a third CDR of SEQ ID NO: 714 and a light chain variable region comprising a first CDR of SEQ ID NO: 715, a second CDR of SEQ ID NO: 716, and a third CDR of SEQ ID NO: 717;

a heavy chain variable region comprising a first CDR of SEQ ID NO: 726, a second CDR of SEQ ID NO: 727, and a third CDR of SEQ ID NO: 728 and a light chain variable region comprising a first CDR of SEQ ID NO: 729, a second CDR of SEQ ID NO: 420, and a third CDR of SEQ ID NO: 730; or

36 - 37 . (canceled)

38 . A polypeptide having a formula of:

PD1VH-ConstantDomain-LinkerA-MAdCAMscFv,

wherein the PD1VH is a PD-1 heavy chain variable domain of any PD-1 antibody provided for herein;

the ConstantDomain is an IgG1 constant domain, or any other constant domain such as IgG2, IgG3, or IgG4;

Linker A is a G/S or a G/A linker, such as those provided herein,

MAdCAMscFv is of the following formula:

MAdCAMVH-LinkerB-MAdCAMVK,

wherein MAdCAMVH is a MAdCAM heavy chain variable domain as provided herein;

Linker B is a G/S or a G/A linker, such as those provided herein; and

MAdCAMVK is a light chain variable domain as provided herein.

39 - 61 . (canceled)

62 . An antibody that binds to PD-1, wherein the antibody comprises a sequence as provided in PD-1 Antibody Table 4 or PD-1 Antibody Table 5.

63 . The antibody of claim 62 , or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:

(i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of any of the CDR1 sequences set forth in the PD-1 Antibody Table 4 or PD-1 Antibody Table 5; the heavy chain CDR2 has the amino acid sequence of any of the CDR2 sequences set forth in the PD-1 Antibody Table 4 or PD-1 Antibody Table 5, and the heavy chain CDR3 has the amino acid sequence of any of the CDR3 sequences set forth in the PD-1 Antibody Table 4 or PD-1 Antibody Table 5, or variants of any of the foregoing; and

(ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of any of the LCDR1 sequences set forth in the PD-1 Antibody Table 4 or PD-1 Antibody Table 5; the light chain LCDR2 has the amino acid sequence of any of the LCDR2 sequences set forth in the PD-1 Antibody Table 4 or PD-1 Antibody Table 5, and the light chain CDR3 has the amino acid sequence of any of the LCDR3 sequences set forth in PD-1 Antibody Table 4 or PD-1 Antibody Table 5, or variants of any of the foregoing.

64 - 77 . (canceled)

78 . The antibody of claim 62 , wherein the antibody that binds to PD-1 is associated, either directly or indirectly, to another moiety.

79 - 85 . (canceled)

86 . A pharmaceutical composition comprising a polypeptide, protein, or an antibody of claim 1 .

87 . A method of treating a subject with a disorder the method comprising administering the polypeptide of claim 1 to the subject to treat the disorder, wherein the disorder is inflammatory bowel disease, Crohn's disease, ulcerative colitis, auto-immune hepatitis, primary sclerosing cholangitis, Type 1 diabetes, GVHD, or other auto-immune disorder described herein.

88 - 99 . (canceled)

100 . A nucleic acid encoding the polypeptide of claim 1 .

101 . (canceled)

102 . A cell comprising the nucleic acid of claim 100 .

103 . A method of making a polypeptide of claim 1 comprising culturing a cell comprising a nucleic acid molecule encoding the polypeptide to make the a polypeptide.

104 . (canceled)

Assignments (1)

CHANGE OF NAME Recorded Oct 13, 2020

From: PANDION THERAPEUTICS, INC.

To: PANDION OPERATIONS, INC.

Reel/Frame 054056/0903 →